Biotest Aktiengesellschaft (ETR:BIO) Shares Down 0.2%

Biotest Aktiengesellschaft (ETR:BIOGet Rating) shares were down 0.2% during trading on Monday . The stock traded as low as €42.80 ($46.52) and last traded at €42.80 ($46.52). Approximately 70 shares traded hands during trading, a decline of 96% from the average daily volume of 1,927 shares. The stock had previously closed at €42.90 ($46.63).

Biotest Aktiengesellschaft Stock Performance

The firm has a market capitalization of $844.85 million and a PE ratio of -31.10. The company has a quick ratio of 1.66, a current ratio of 4.54 and a debt-to-equity ratio of 158.90. The firm has a 50-day moving average price of €42.95 and a 200 day moving average price of €42.52.

About Biotest Aktiengesellschaft

(Get Rating)

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis.

Featured Articles

Receive News & Ratings for Biotest Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotest Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.